Home India News US News Chat with PDF Document Cheap Flights Hotel Booking Play & Earn Web Hosting Mock Test Filmybaap Contact Us Advertise Zordo Products

Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly

5 months ago 71

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.'s shares climbed in early US trading after its experimental drug for Alzheimer's slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.

AJ Mast | Bloomberg | Getty Images

Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that's good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market.

Read Entire Article